Sponsored by
These are exciting trials.
It is nice to see more research on other uses for the Optune device.
1. Optune trial opens for patients with low grade gliomas
A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas
This trial will compare the use of Optune alone against the use of Optune combined with Temodar, in patients with low grade gliomas.
The Temodar will be using a metronomic schedule (daily low dose instead of 5 days of high dose per month) for 1 year. Optune will be used in both arms for 1 year.
2. Optune trial opens for pediatric patients with high grade gliomas! This is a trial of the Optune NovoTTF-200A System With and Without Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Gliomas